A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)
Status:
Completed
Trial end date:
2013-10-10
Target enrollment:
Participant gender:
Summary
This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations
more effectively than placebo in participants with overactive bladder (OAB). The primary
hypothesis of the base study is that administration of vibegron demonstrates a dose-related
reduction, compared with placebo, in average number of daily micturitions in participants
with OAB after 8 weeks of treatment.